Koff WC - Search Results

1

Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals.

Seth A, Yasutomi Y, Jacoby H, Callery JC, Kaminsky SM, Koff WC, Nixon DF, Letvin NL. Seth A, et al. Among authors: koff wc. AIDS Res Hum Retroviruses. 2000 Mar 1;16(4):337-43. doi: 10.1089/088922200309214. AIDS Res Hum Retroviruses. 2000. PMID: 10716371 Clinical Trial.

2

CTL induction using synthetic peptides delivered in emulsions--critical role of the formulation procedure.

Singh M, Hioe C, Qiu H, Li XM, Wang CY, Koff W, Zamb T, Nixon DF. Singh M, et al. Vaccine. 1997 Nov;15(16):1773-8. doi: 10.1016/s0264-410x(97)00109-6. Vaccine. 1997. PMID: 9364682 Free article.

3

Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides.

Hioe CE, Qiu H, Chend PD, Bian Z, Li ML, Li J, Singh M, Kuebler P, McGee P, O'Hagan D, Zamb T, Koff W, Allsopp C, Wang CY, Nixon DF. Hioe CE, et al. Vaccine. 1996 Apr;14(5):412-8. doi: 10.1016/0264-410x(95)00191-3. Vaccine. 1996. PMID: 8735553 Free article.

4

Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity.

Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY, O'Hagan D. Nixon DF, et al. Vaccine. 1996 Nov;14(16):1523-30. doi: 10.1016/s0264-410x(96)00099-0. Vaccine. 1996. PMID: 9014294 Free article.

5

HIV-1 rational vaccine design: molecular details of b12-gp120 complex structure.

Phogat SK, Kaminsky SM, Koff WC. Phogat SK, et al. Among authors: koff wc. Expert Rev Vaccines. 2007 Jun;6(3):319-21. doi: 10.1586/14760584.6.3.319. Expert Rev Vaccines. 2007. PMID: 17542747 No abstract available.

6

Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection.

Champiat S, Raposo RA, Maness NJ, Lehman JL, Purtell SE, Hasenkrug AM, Miller JC, Dean H, Koff WC, Hong MA, Martin JN, Deeks SG, Spotts GE, Pilcher CD, Hecht FM, Kallas EG, Garrison KE, Nixon DF. Champiat S, et al. Among authors: koff wc. PLoS One. 2012;7(6):e39311. doi: 10.1371/journal.pone.0039311. Epub 2012 Jun 29. PLoS One. 2012. PMID: 22768072 Free PMC article.

7

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW; Protocol G Principal Investigators; Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. Walker LM, et al. Among authors: koff wc. Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3. Science. 2009. PMID: 19729618 Free PMC article.

8

Future directions in HIV vaccine development.

Koff WC, Glass MJ. Koff WC, et al. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1313-5. doi: 10.1089/aid.1992.8.1313. AIDS Res Hum Retroviruses. 1992. PMID: 1466948 No abstract available.

9

The next steps in HIV vaccine development.

Ada G, Koff W, Petricciani J. Ada G, et al. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1317-9. doi: 10.1089/aid.1992.8.1317. AIDS Res Hum Retroviruses. 1992. PMID: 1466949 Review. No abstract available.

10

Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine.

Haubrich RH, Takeda A, Koff W, Smith G, Ennis FA. Haubrich RH, et al. J Infect Dis. 1992 Mar;165(3):545-8. doi: 10.1093/infdis/165.3.545. J Infect Dis. 1992. PMID: 1538159 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

132 results

Search Page